8-K

SERES THERAPEUTICS, INC.

Date: April 8, 2024

/s/ Thomas J. DesRosier

Name: Thomas J. DesRosier

Title: Executive Vice President and Chief Legal Officer

0001193125-24-089654.txt : 20240408 0001193125-24-089654.hdr.sgml : 20240408 20240408163055 ACCESSION NUMBER: 0001193125-24-089654 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240404 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 24829982 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 8-K 1 d798362d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2024

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37465

27-4326290

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

101 Cambridgepark Drive

Cambridge, MA

02140

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.001 per share

MCRB

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On April 4, 2024, Seres Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s Common Stock, $0.001 par value per share, from 240,000,000 shares to 360,000,000 shares, as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 5, 2024.

The Company’s board of directors previously approved the Amendment and, on April 5, 2024, the Company filed a Certificate of Amendment to the Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Amendment, which became effective upon filing with the Secretary of State.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On April 4, 2024, at the Annual Meeting a total of 104,354,210 shares of the Company’s Common Stock were present electronically or represented by proxy at the meeting, representing approximately 71.69% of the Company’s outstanding Common Stock as of the February 12, 2024 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on March 5, 2024.

Item 1 - Election of two Class III directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.


NOMINEE	Votes FOR	Votes WITHHELD	Broker Non-Votes
Paul R. Biondi	53,477,829	29,111,829	21,764,552
Kurt C. Graves	51,107,660	31,481,998	21,764,552

Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
100,843,550	2,910,775	599,885	0

Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
52,923,699	29,004,971	660,988	21,764,552

Item 4 - Approval of an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
81,471,934	21,346,140	1,536,136	0

Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
83,248,729	19,390,195	1,715,286	0

Item 6 – A stockholder proposal on Simple Majority Vote.


Votes FOR	Votes AGAINST	Votes ABSTAINED	Broker Non-Votes
52,117,624	29,641,877	830,157	21,764,552

Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 6 were approved.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

3.1		Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-3.1 2 d798362dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

RESTATED CERTIFICATE OF INCORPORATION

SERES THERAPEUTICS, INC.

Pursuant to Section 242 of the

General Corporation Law of the State of Delaware

Seres Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY THAT:

1. The Board of Directors of the Corporation duly adopted resolutions recommending and declaring advisable that the Restated Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), be amended and that such amendment be submitted to the stockholders of the Corporation for their consideration, as follows:

RESOLVED, that the Certificate of Incorporation be amended by amending and restating the first sentence of Article FOURTH of the Certificate of Incorporation in its entirety to read as follows:

“The total number of shares of all classes of stock that the Corporation shall have authority to issue is 370,000,000 shares, consisting of (a) 360,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”), and (b) 10,000,000 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).”

2. The stockholders of the Corporation duly approved such amendment at an annual meeting of the stockholders of the Corporation.

3. Such amendment has been duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, this Certificate of Amendment to Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 5^th day of April, 2024.


By:		/s/ Eric D. Shaff
Name:		Eric D. Shaff
Title:		President and Chief Executive Officer

EX-101.SCH 3 mcrb-20240404.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mcrb-20240404_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mcrb-20240404_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Apr. 04, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001609809
Current Fiscal Year End Date	--12-31
Document Type	8-K
Document Period End Date	Apr. 04, 2024
Entity Registrant Name	SERES THERAPEUTICS, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-37465
Entity Tax Identification Number	27-4326290
Entity Address, Address Line One	101 Cambridgepark Drive
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	(617)
Local Phone Number	945-9626
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common stock, par value $0.001 per share
Trading Symbol	MCRB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d798362d8k.htm mcrb-20240404.xsd mcrb-20240404_lab.xml mcrb-20240404_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d798362d8k.htm": { "nsprefix": "mcrb", "nsuri": "http://serestherapeutics.com/20240404", "dts": { "inline": { "local": [ "d798362d8k.htm" ] }, "schema": { "local": [ "mcrb-20240404.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "mcrb-20240404_lab.xml" ] }, "presentationLink": { "local": [ "mcrb-20240404_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-04_to_2024-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d798362d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-04_to_2024-04-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d798362d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://serestherapeutics.com//20240404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-089654-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-089654-xbrl.zip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end XML 17 d798362d8k_htm.xml IDEA: XBRL DOCUMENT 0001609809 2024-04-04 2024-04-04 false 0001609809 --12-31 8-K 2024-04-04 SERES THERAPEUTICS, INC. DE 001-37465 27-4326290 101 Cambridgepark Drive Cambridge MA 02140 (617) 945-9626 false false false false Common stock, par value $0.001 per share MCRB NASDAQ false